Skip to main content

Table 2 In vivo experimental data of radiosensitization effects

From: CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Authors CDK4/6 inhibitor Xenograft Efficacy with radiotherapy
Hashizume et al. [42] Palbociclib Intracranial ATRT
(BT12)
(BT16)
Glioblastoma
(GBM43)
Median survival time increased by 24 to 26 days (1.4-fold)
Median survival time increased by 31.5 to 34.5 days (3.3-fold)
Median survival time increased by 10 to 13.5 days (1.6-fold)
Whittaker et al. [43] Palbociclib Glioblastoma
(RN1)
Median survival time increased by 8 days
Naz et al. [44] Abemaciclib NSCLC
(H460)
Tumor regrowth delay 8 and 9 days, inhibit IR-induced tumor vasculogenesis
Tao et al. [30] Palbociclib and Trametinib NSCLC
(A549)
Tumor volume ↓
Proliferation ↓
Apoptosis ↑
Huang et al. [45] Palbociclib HCC
(Huh7)
Tumor volume ↓
Tumor weight ↓
Li et al. [50] Ribociclib and CA3 EAC
(Flo-1 XTR)
Tumor volume ↓
Tumor weight ↓
Barton et al. [52] Palbociclib Ink4a-ARF- deficient BSG a mouse model Median survival time increased by 10 days (19%)
  1. a BSG, brainstem glioma